Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A for Raynaud Phenomenon in Systemic Sclerosis
NCT03717961Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Onabotulinumtoxina + hydrogel in Raynaud phenomenon (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Absolute change from baseline in the number of RP attacks per week at 4 weeks. Started Oct 2018; status: completed.
02
Drugs
Onabotulinumtoxina + hydrogel
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT03717961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717961.